NCT06209177View on ClinicalTrials.gov

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

September 30, 2025

Conditions
IgA Nephropathy
Interventions
DRUG

ARO-CFB

ARO-CFB for sc injection

DRUG

Placebo

sterile normal saline (0.9% NaCl for sc injection)

Trial Locations (1)

1010

Research Site, Auckland

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY